
To assess the efficacy and safety of liraglutide to reduce visceral and ectopic fat in adults with or without type 2 diabetes mellitus(T2DM). Four databases were searched up to 6 May 2022 for RCTs assessing the effect of liraglutide on visceral and ectopic fat. Sixteen RCTs with a total of 845 participants were included in the meta‐analysis. Liraglutide significantly and safely reduces visceral and ectopic liver fat irrespective of T2DM status and reduces visceral fat provided adequate dosage and duration of therapy are ensured.
Like
Save
Share